South African pharmaceutical firm iDexis is fighting back against local healthcare regulators over its Compounded GLP-1 Weight-Loss Injections. The company strongly defends its product safety amid serious compliance allegations. The dispute follows a joint statement by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC). The regulators ordered an immediate recall of the company’s…
Tag: Tirzepatide
-
Unregistered GLP-1 Medicines Crackdown Escalates In SA
The national medicines regulator has intensified its enforcement action against the unlawful manufacture and distribution of unregistered GLP-1 therapies. This development comes as concerns grow over South Africa’s rapidly expanding and largely unregulated weight-loss drug market. The South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) confirmed they seized several injectable products. The raid took…
-
GLP-1 Weight Loss Drugs Reshape Obesity Care In South Africa
South Africa’s fight against obesity has entered a decisive phase, driven by a surge in the medicalisation of treatment through GLP-1 weight loss drugs. In early 2026, two major medications, Mounjaro (tirzepatide) and Wegovy (semaglutide), have received key regulatory approvals, marking a new chapter in primary healthcare. With nearly 4.5 million South African adults living with obesity, the shift comes…
-
Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen targeting Mounjaro expansion will bring the high-demand drug Mounjaro to Sub-Saharan Africa. Mounjaro is also known as tirzepatide. Launches across the continent are anticipated in 2026. CEO Stephen Saad confirmed this plan. He announced it in his annual letter to shareholders. The move follows major success in South Africa. It also comes after a new regulatory approval. This approval…
-
Aspen Boosted by Mounjaro: A New Era in Weight Loss
Aspen Pharmacare’s share price saw a notable increase. This followed the announcement that the high-profile diabetes drug, Mounjaro (tirzepatide), has received approval from the South African Health Products Regulatory Authority (SAHPRA) for use as a chronic weight management treatment. Aspen was notably boosted by Mounjaro’s approval, signalling a positive development for the company. The JSE-listed pharmaceutical giant confirmed that SAHPRA…